Non-Vegetarian Ingredient In Herbal Tooth Powder, Delhi HC Issues Notice To Patanjali Ayurveda And Baba Ramdev

New Delhi: Patanjali Ayurved Limited, led by yoga guru Ramdev, is once again under legal scrutiny as the Delhi high court has demanded responses from the Centre, the Food Safety and Standards Authority of India (FSSAI), and the company over a petition alleging misbranding of its “Divya Dant Manjan” dental care product.

The petition, filed by lawyer Yatin Sharma, claims that despite “Divya Dant Manjan” being marketed with a green dot — an indicator of vegetarian status — it actually contains “samudraphen,” a fish-derived compound.

This, according to Sharma, constitutes “misbranding” under the Drugs and Cosmetics Act. Although the law does not mandate specific labelling for drugs as vegetarian or non-vegetarian, the use of the green dot qualifies as “misbranding” under the Drugs and Cosmetics Act, the petitioner’s counsel argued.

Justice Sanjeev Narula issued notice to the Centre, the FSSAI as well as Patanjali, Divya Pharmacy, Yoga guru Ramdev and other related parties on Sharma’s petition.

The petitioner, represented by advocates Swapnil Chaudhary and Prashant Gupta, said the discovery was “distressing” for him and his family, particularly because they adhere to a strict vegetarian diet due to religious beliefs.

“Respondent No. 3 (Patanjali Ayurveda) is selling the same product with a green dot on their official website, indicating that the product is vegetarian in nature, which is contradictory.

“The Petitioner seeks redressal for the profound distress caused by the inadvertent consumption of a non-vegetarian product, emphasizing the importance of upholding religious beliefs and ensuring transparency in product representation,” the petition, filed through lawyers Mohit Solanki and Pulkit Chaudhary, stated.

The matter would be heard next in November.

Related Posts

  • Pharma
  • June 24, 2025
  • 81 views
Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). The drug is a specially designed anti-PD-1 monoclonal…

  • Pharma
  • June 24, 2025
  • 81 views
India’s herbal and ayurvedic OTC market set to outpace global growth

New Delhi: India’s herbal and ayurvedic OTC (over the counter) market is expected to grow at a CAGR of 6.5 per cent, from $69 million in 2025 to $118 million…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharma launches TEVIMBRA in India

India’s herbal and ayurvedic OTC market set to outpace global growth

India’s herbal and ayurvedic OTC market set to outpace global growth

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug